---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115048"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T14:23:34.845249+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Milestone to host webcast Nov 13 on etripamil Phase 2 AFib-RVR study results

## Summary
- Webcast on Monday Nov 13, 2023 at 8:00 a.m. ET to discuss ReVeRA Phase 2 results of etripamil in AFib-RVR.
- Key opinion leaders A. John Camm, MD, and Sean Pokorney, MD, will join the webcast.
- Results presented as Featured Science at AHA Scientific Sessions 2023.
- Dial-in: (877) 870-4263 (domestic) or (412) 317-0790 (international).
- Webcast and slides accessible via News & Events section of Milestone's IR website.

## SEC filing metadata
- accession: 0001104659-23-115048
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465923115048/0001104659-23-115048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465923115048/tm2330059d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115048
- JSON: https://secwatch.observer/filing/0001104659-23-115048.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.